Farah Toron1, Maureen P Neary2, Timothy W Smith3, David Gruben4, William Romero5, Amy Cha3, Keyur Patel1, Simona Z Vasileva6, Mahreen Ameen7. 1. Health Economics and Outcomes Research, Real World Solutions, IQVIA, 210 Pentonville Road, London, N1 9JY, UK. 2. Inflammation & Immunology, Pfizer Inc, Collegeville, Pennsylvania, USA. 3. Inflammation & Immunology, Pfizer Inc, New York, New York, USA. 4. Global Biometrics and Data Management (Statistics), Pfizer Inc, Groton, Connecticut, USA. 5. Inflammation & Immunology, Pfizer Ltd, Surrey, UK. 6. Health Economics and Outcomes Research, Real World Solutions, IQVIA, 210 Pentonville Road, London, N1 9JY, UK. simona.vasileva@iqvia.com. 7. Royal Free London National Health Services Foundation Trust, London, UK.
Abstract
INTRODUCTION: The burden of mild-to-moderate atopic dermatitis (AD) in the United Kingdom (UK) is not well understood. Long-lasting AD flares may lead to systemic inflammation resulting in reversible progression from mild to more severe AD. This study aimed to assess the clinical and economic burden of mild-to-moderate AD in the UK. METHODS: AD patients were identified in the Health Improvement Network (THIN) from 2013 to 2017 and propensity score matched to non-AD controls by demographics. Patients were identified based on continuous disease activity using validated algorithms and sufficient patient status to fully validate data integrity for the entire period. Mild-to-moderate AD patients were identified by using treatment as a surrogate. Demographics, clinical characteristics and healthcare resource use (HCRU) were obtained from THIN. Literature reviews were conducted to obtain additional outcomes. A cost-of-illness model was developed to extrapolate the burden in 2017 to the UK population and in subsequent years (2018-2022). RESULTS: In 2017, the prevalence of mild-to-moderate AD in THIN was 1.28%. These patients reported higher comorbidity rates and significantly higher (p < 0.0001) HCRU, encompassing mean general practitioner visits (5.57 versus 3.59), AD-related prescriptions (5.85 versus 0.68) and total referrals (0.97 versus 0.82) versus matched non-AD controls. The model projected total HCRU and drug excess costs of €462.99M over the 5 years. The excess cost decreased to €417.35M after excluding patients on very potent topical corticosteroids, who most likely had at least moderate disease. The excess costs increased to €1.21B and €7.06B when considering comorbidity burden and productivity losses, respectively. CONCLUSION: Mild-to-moderate AD patients had higher comorbidity burden, HCRU and cost compared with matched non-AD controls. Overall, UK country-based economic burden was high given partly the high prevalence of this disease. Moreover, productivity burden and comorbidities had considerable impact on the economic burden, which further suggests the importance of optimal disease management.
INTRODUCTION: The burden of mild-to-moderate atopic dermatitis (AD) in the United Kingdom (UK) is not well understood. Long-lasting AD flares may lead to systemic inflammation resulting in reversible progression from mild to more severe AD. This study aimed to assess the clinical and economic burden of mild-to-moderate AD in the UK. METHODS: AD patients were identified in the Health Improvement Network (THIN) from 2013 to 2017 and propensity score matched to non-AD controls by demographics. Patients were identified based on continuous disease activity using validated algorithms and sufficient patient status to fully validate data integrity for the entire period. Mild-to-moderate AD patients were identified by using treatment as a surrogate. Demographics, clinical characteristics and healthcare resource use (HCRU) were obtained from THIN. Literature reviews were conducted to obtain additional outcomes. A cost-of-illness model was developed to extrapolate the burden in 2017 to the UK population and in subsequent years (2018-2022). RESULTS: In 2017, the prevalence of mild-to-moderate AD in THIN was 1.28%. These patients reported higher comorbidity rates and significantly higher (p < 0.0001) HCRU, encompassing mean general practitioner visits (5.57 versus 3.59), AD-related prescriptions (5.85 versus 0.68) and total referrals (0.97 versus 0.82) versus matched non-AD controls. The model projected total HCRU and drug excess costs of €462.99M over the 5 years. The excess cost decreased to €417.35M after excluding patients on very potent topical corticosteroids, who most likely had at least moderate disease. The excess costs increased to €1.21B and €7.06B when considering comorbidity burden and productivity losses, respectively. CONCLUSION: Mild-to-moderate AD patients had higher comorbidity burden, HCRU and cost compared with matched non-AD controls. Overall, UK country-based economic burden was high given partly the high prevalence of this disease. Moreover, productivity burden and comorbidities had considerable impact on the economic burden, which further suggests the importance of optimal disease management.
Authors: S Barbarot; S Auziere; A Gadkari; G Girolomoni; L Puig; E L Simpson; D J Margolis; M de Bruin-Weller; L Eckert Journal: Allergy Date: 2018-02-13 Impact factor: 13.146
Authors: C Dharma; D L Lefebvre; M M Tran; W Y W Lou; P Subbarao; A B Becker; P J Mandhane; S E Turvey; M R Sears Journal: Clin Exp Allergy Date: 2017-12-15 Impact factor: 5.018
Authors: Lawrence F Eichenfield; Mark Boguniewicz; Eric L Simpson; John J Russell; Julie K Block; Steven R Feldman; Adele R Clark; Susan Tofte; Jeffrey D Dunn; Amy S Paller Journal: Pediatrics Date: 2015-08-03 Impact factor: 7.124
Authors: Jochen Schmitt; Kristin Schwarz; Hansjörg Baurecht; Melanie Hotze; Regina Fölster-Holst; Elke Rodríguez; Young A E Lee; Andre Franke; Frauke Degenhardt; Wolfgang Lieb; Christian Gieger; Michael Kabesch; Markus M Nöthen; Alan D Irvine; W H Irwin McLean; Stefanie Deckert; Victoria Stephan; Peter Schwarz; Martin Aringer; Natalija Novak; Stephan Weidinger Journal: J Allergy Clin Immunol Date: 2015-08-04 Impact factor: 10.793
Authors: Florence J Dalgard; Uwe Gieler; Lucia Tomas-Aragones; Lars Lien; Francoise Poot; Gregor B E Jemec; Laurent Misery; Csanad Szabo; Dennis Linder; Francesca Sampogna; Andrea W M Evers; Jon Anders Halvorsen; Flora Balieva; Jacek Szepietowski; Dmitry Romanov; Servando E Marron; Ilknur K Altunay; Andrew Y Finlay; Sam S Salek; Jörg Kupfer Journal: J Invest Dermatol Date: 2014-12-18 Impact factor: 8.551
Authors: Katrina Abuabara; Morgan Ye; Charles E McCulloch; Alice Sullivan; David J Margolis; David P Strachan; Lavinia Paternoster; Yik Weng Yew; Hywel C Williams; Sinéad M Langan Journal: J Allergy Clin Immunol Date: 2019-06-28 Impact factor: 10.793